

Robert A Byrne Mb Bch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/107560/publications.pdf>

Version: 2024-02-01

327
papers

32,172
citations

6592

79
h-index

4535

171
g-index

363
all docs

363
docs citations

363
times ranked

21825
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	1.0	4,537
2	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1289-1367.	1.0	3,048
3	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	1.0	2,246
4	Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. <i>Journal of Experimental Medicine</i> , 2012, 209, 819-835.	4.2	1,441
5	A Randomized Clinical Trial to Evaluate the Safety and Efficacy of a Percutaneous Left Ventricular Assist Device Versus Intra-Aortic Balloon Pumping for Treatment of Cardiogenic Shock Caused by Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1584-1588.	1.2	904
6	Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR _{CT} : outcome and resource impacts study. <i>European Heart Journal</i> , 2015, 36, 3359-3367.	1.0	467
7	Current Treatment of In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2659-2673.	1.2	443
8	Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas GrÃ¼ntzig Lecture ESC 2014. <i>European Heart Journal</i> , 2015, 36, 3320-3331.	1.0	441
9	Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. <i>European Heart Journal</i> , 2018, 39, 3281-3300.	1.0	431
10	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	1.6	428
11	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	0.6	402
12	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1619-1629.	1.2	401
13	5-Year Prognostic Value of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2383-2389.	1.2	380
14	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2019, 14, 1435-1534.	1.4	367
15	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. <i>European Heart Journal</i> , 2015, 36, 1252-1263.	1.0	366
16	Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. <i>European Heart Journal</i> , 2015, 36, 2147-2159.	1.0	362
17	Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. <i>European Heart Journal</i> , 2012, 33, 1214-1222.	1.0	359
18	Incidence and predictors of restenosis after coronary stenting in 10,004 patients with surveillance angiography. <i>Heart</i> , 2014, 100, 153-159.	1.2	351

#	ARTICLE	IF	CITATIONS
19	Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. <i>Lancet, The</i> , 2013, 381, 461-467.	6.3	347
20	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2017, 38, 3382-3390.	1.0	335
21	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	1.0	335
22	Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2008, 359, 688-696.	13.9	323
23	Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2016, 387, 537-544.	6.3	317
24	1-Year Outcomes of FFRCT-Guided Care in Patients With Suspected Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 435-445.	1.2	313
25	Risk of Stent Thrombosis Among Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Second-Generation Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1267-1274.	1.1	286
26	Abciximab and Heparin versus Bivalirudin for Non-ST-Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2011, 365, 1980-1989.	13.9	285
27	Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. <i>Lancet, The</i> , 2015, 386, 655-664.	6.3	261
28	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	0.6	261
29	European expert consensus on rotational atherectomy. <i>EuroIntervention</i> , 2015, 11, 30-36.	1.4	247
30	Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. <i>European Heart Journal</i> , 2009, 30, 2714-2721.	1.0	224
31	2017 European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (EAACC). <i>European Heart Journal</i> , 2017, 38, 2159-2170.	0.7	209
32	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. <i>European Heart Journal</i> , 2009, 30, 2441-2449.	1.0	207
33	Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2012, 125, 1424-1431.	1.6	207
34	Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis. <i>Circulation</i> , 2017, 136, 1007-1021.	1.6	200
35	Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials. <i>BMJ, The</i> , 2012, 345, e5170-e5170.	3.0	196
36	Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2710-2716.	1.2	192

#	ARTICLE	IF	CITATIONS
37	Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. <i>European Heart Journal</i> , 2019, 40, 2566-2584.	1.0	189
38	Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. <i>European Heart Journal</i> , 2015, 36, 2608-2620.	1.0	187
39	Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. <i>European Heart Journal</i> , 2008, 29, 1975-1982.	1.0	182
40	Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1760-1768.	1.2	180
41	Drug-coated balloon therapy in coronary and peripheral artery disease. <i>Nature Reviews Cardiology</i> , 2014, 11, 13-23.	6.1	180
42	Coronary balloon angioplasty, stents, and scaffolds. <i>Lancet, The</i> , 2017, 390, 781-792.	6.3	179
43	No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. <i>European Heart Journal</i> , 2011, 32, 1605-1613.	1.0	174
44	Prognostic value of coronary computed tomography angiography during 5 years of follow-up in patients with suspected coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 3277-3285.	1.0	174
45	Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. <i>Lancet, The</i> , 2019, 393, 2503-2510.	6.3	166
46	Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. <i>Lancet, The</i> , 2011, 378, 1071-1078.	6.3	164
47	Quality-of-Life and Economic Outcomes of Assessing Fractional Flow Reserve With Computed Tomography Angiography. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2315-2323.	1.2	164
48	High-Speed Rotational Atherectomy Versus Modified Balloons Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007415.	1.4	164
49	Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1981.	3.8	162
50	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 408-417.	0.6	160
51	Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent Polymer. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 291-299.	1.1	156
52	Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. <i>European Heart Journal</i> , 2016, 37, 1538.1-1549.	1.0	147
53	Biodegradable Polymer Versus Permanent Polymer Drug-Eluting Stents and Everolimus- Versus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1325-1331.	1.2	131
54	Polymer-Free Sirolimus- and Probucol-Eluting Versus New Generation Zotarolimus-Eluting Stents in Coronary Artery Disease. <i>Circulation</i> , 2011, 124, 624-632.	1.6	126

#	ARTICLE	IF	CITATIONS
55	A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. <i>European Heart Journal</i> , 2008, 30, 923-931.	1.0	123
56	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). <i>European Heart Journal</i> , 2020, 41, 3715-3728.	1.0	121
57	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. <i>Europace</i> , 2017, 19, euw141.	0.7	120
58	Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 582-589.	1.4	117
59	Mechanisms of Very Late Bioresorbable Scaffold Thrombosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2330-2344.	1.2	117
60	Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2012, 33, 3078-3087.	1.0	115
61	2-Year Clinical and Angiographic Outcomes From a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents Versus Polymer-Based Cypher and Endeavor, Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2536-2543.	1.2	108
62	Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis. <i>JAMA Cardiology</i> , 2017, 2, 1079.	3.0	99
63	Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. <i>European Heart Journal</i> , 2015, 36, 94-99.	1.0	98
64	Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1332-1340.	1.1	98
65	Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. <i>Circulation</i> , 2019, 139, 325-333.	1.6	97
66	Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. <i>Heart</i> , 2009, 95, 1489-1494.	1.2	96
67	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2664-2678.	1.2	93
68	Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes. <i>European Heart Journal</i> , 2008, 29, 2868-2876.	1.0	92
69	Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. <i>EuroIntervention</i> , 2018, 14, 656-677.	1.4	92
70	Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. <i>American Heart Journal</i> , 2009, 157, 620-624.e2.	1.2	91
71	Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. <i>American Heart Journal</i> , 2011, 161, 68-75.	1.2	90
72	Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2021, 42, 308-319.	1.0	90

#	ARTICLE	IF	CITATIONS
73	High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2259-2268.	1.2	88
74	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. <i>EuroIntervention</i> , 2016, 12, 103-111.	1.4	88
75	Current use of intracoronary imaging in interventional practice â€“ Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. <i>EuroIntervention</i> , 2018, 14, e475-e484.	1.4	87
76	Polymer coatings and delayed arterial healing following drug-eluting stent implantation. <i>Minerva Cardioangiologica</i> , 2009, 57, 567-84.	1.2	87
77	Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 877-884.	1.1	85
78	Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. <i>Journal of Internal Medicine</i> , 2008, 264, 472-480.	2.7	82
79	Multiple source surveillance incidence and aetiology of out-of-hospital sudden cardiac death in a rural population in the West of Ireland. <i>European Heart Journal</i> , 2008, 29, 1418-1423.	1.0	81
80	Drug-Coated Balloon Versus Plain BalloonÂAngioplasty for the Treatment ofÂFemoropopliteal Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1731-1742.	1.1	80
81	Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. <i>EuroIntervention</i> , 2011, 7, 730-737.	1.4	77
82	Tissue Characterization After Drug-Eluting Stent Implantation Using Optical Coherence Tomography. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1376-1383.	1.1	70
83	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1017-1028.	1.2	70
84	Prognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2008, 52, 512-517.	1.2	69
85	Zotarolimus- Versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2075-2082.	1.2	69
86	Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis. <i>Thrombosis and Haemostasis</i> , 2011, 105, 864-872.	1.8	66
87	Drug-Eluting Stents in Percutaneous Coronary Intervention. <i>Drug Safety</i> , 2009, 32, 749-770.	1.4	63
88	High platelet reactivity and clinical outcome â€“ Fact and fiction. <i>Thrombosis and Haemostasis</i> , 2011, 106, 191-202.	1.8	63
89	Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	63
90	State of the art: coronary artery stents â€“ past, present and future. <i>EuroIntervention</i> , 2017, 13, 706-716.	1.4	63

#	ARTICLE	IF	CITATIONS
91	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. <i>EuroIntervention</i> , 2016, 11, 1372-137.	1.4	60
92	Everolimus-Eluting Versus Sirolimus-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 371-377.	1.4	55
93	Peak Cardiac Troponin-T Level, Scintigraphic Myocardial Infarct Size and One-Year Prognosis in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2010, 106, 1212-1217.	0.7	53
94	Randomized Trial of Polymer-Free Sirolimus- and Probuocol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 784-792.	1.1	52
95	Efficacy Over Time With Drug-Eluting Stents in Saphenous Vein Graft Lesions. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1973-1982.	1.2	52
96	Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. <i>European Heart Journal</i> , 2008, 30, 290-296.	1.0	51
97	Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents. <i>Journal of the American College of Cardiology</i> , 2017, 70, 60-74.	1.2	51
98	10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2020, 76, 146-158.	1.2	49
99	Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. <i>EuroIntervention</i> , 2015, 11, 68-74.	1.4	48
100	Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: Final results of the intracoronary stenting and angiographic restenosis test equivalence between two drug-eluting stents (ISAR-TEST) trial. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, E23-8.	0.7	47
101	Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. <i>EuroIntervention</i> , 2013, 9, 797-802.	1.4	47
102	Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2012, 101, 461-467.	1.5	46
103	Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. <i>European Heart Journal</i> , 2018, 39, 1591-1601.	1.0	45
104	Vascular access and closure in coronary angiography and percutaneous intervention. <i>Nature Reviews Cardiology</i> , 2013, 10, 27-40.	6.1	44
105	Impact of Coronary Anatomy and Stenting Technique on Long-Term Outcome After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 29-36.	1.1	44
106	Duration of Dual Antiplatelet Therapy and Long-Term Clinical Outcome After Coronary Drug-Eluting Stent Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 381-391.	1.4	43
107	Safety and Efficacy of a Potential Treatment Algorithm by Using Manual Compression Repair and Ultrasound-Guided Thrombin Injection for the Management of Iatrogenic Femoral Artery Pseudoaneurysm in a Large Patient Cohort. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 207-215.	1.4	43
108	Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. <i>American Heart Journal</i> , 2013, 166, 534-540.	1.2	42

#	ARTICLE	IF	CITATIONS
109	Prognostic value of late gadolinium enhancement in cardiovascular magnetic resonance imaging after acute ST-elevation myocardial infarction in comparison with single-photon emission tomography using Tc99m-Sestamibi. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 216-225.	0.5	41
110	Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. <i>European Heart Journal</i> , 2019, 40, 167-176.	1.0	40
111	Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2015, 11, 196-203.	1.4	38
112	No Association of <i>ABC1</i> C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 82-88.	1.4	37
113	Aspiration thrombectomy in patients undergoing primary angioplasty: Totality of data to 2013. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 973-977.	0.7	37
114	Implementing the new European Regulations on medical devices—clinical responsibilities for evidence-based practice: a report from the Regulatory Affairs Committee of the European Society of Cardiology. <i>European Heart Journal</i> , 2020, 41, 2589-2596.	1.0	37
115	Patterns of Presentation and Outcomes of Patients with Acute Coronary Syndromes. <i>Cardiology</i> , 2009, 113, 198-206.	0.6	36
116	Neoatherosclerosis in Patients With Coronary Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1340-1350.	1.1	35
117	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.	1.2	35
118	Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2018, 13, 1565-1573.	1.4	35
119	Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. <i>EuroIntervention</i> , 2018, 13, 1574-1586.	1.4	35
120	Comparative efficacy of 2 zotarolimus-eluting stent generations: Resolute versus endeavor stents in patients with coronary artery disease. <i>American Heart Journal</i> , 2013, 165, 80-86.	1.2	33
121	Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 495-504.	0.7	33
122	Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging. <i>Minerva Cardioangiologica</i> , 2012, 60, 473-89.	1.2	33
123	Transfemoral Approach for Coronary Angiography and Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2269-2279.	1.1	32
124	Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006752.	1.4	32
125	European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. <i>European Heart Journal</i> , 2021, 42, 1545-1553.	1.0	32
126	Current Use of Intracoronary Imaging in Interventional Practice—Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. <i>Circulation Journal</i> , 2018, 82, 1360-1368.	0.7	31

#	ARTICLE	IF	CITATIONS
127	Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. <i>International Journal of Cardiology</i> , 2013, 168, 5162-5166.	0.8	29
128	Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 182-189.	0.7	29
129	Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 42.	0.4	29
130	Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. <i>Thrombosis and Haemostasis</i> , 2010, 104, 626-632.	1.8	28
131	Clinical Use of Clopidogrel. <i>Current Pharmaceutical Design</i> , 2012, 18, 5224-5239.	0.9	28
132	Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 822-829.	0.7	28
133	Super high-pressure balloon versus scoring balloon to prepare severely calcified coronary lesions: the ISAR-CALC randomised trial. <i>EuroIntervention</i> , 2021, 17, 481-488.	1.4	28
134	Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 156-162.	0.3	26
135	Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1222-1229.	1.1	26
136	Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1989-1999.	1.8	26
137	Prognostic Value of Kidney Function in Patients With ST-Elevation and Non-ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. <i>American Journal of Kidney Diseases</i> , 2009, 54, 830-839.	2.1	25
138	Effects of verbal suggestion on coronary arteries: Results of a randomized controlled experimental investigation during coronary angiography. <i>American Heart Journal</i> , 2011, 162, 507-511.	1.2	24
139	Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2015, 104, 887-901.	1.5	24
140	Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 772-795.	1.9	24
141	Vascular healing in drug-eluting stents: differential drug-associated response of limus-eluting stents in a preclinical model of stent implantation. <i>EuroIntervention</i> , 2012, 8, 752-759.	1.4	24
142	Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. <i>Heart and Vessels</i> , 2010, 25, 27-34.	0.5	23
143	Pharmacological inhibition of coronary restenosis: systemic and local approaches. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2155-2171.	0.9	23
144	Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention. <i>Clinical Science</i> , 2009, 116, 651-658.	1.8	22

#	ARTICLE	IF	CITATIONS
145	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>European Heart Journal</i> , 2018, 39, e1-e33.	1.0	22
146	Outcome after new generation single-layer polytetrafluoroethylene-covered stent implantation for the treatment of coronary artery perforation. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 912-920.	0.7	22
147	The Extracellular Matrix Metalloproteinase Inducer (EMMPRIN, CD147) - a potential novel target in atherothrombosis prevention?. <i>Thrombosis Research</i> , 2013, 131, 474-480.	0.8	21
148	Bioresorbable Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 198-200.	1.1	21
149	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. <i>EuroIntervention</i> , 2015, 10, 1015-1021.	1.4	21
150	Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1142-1148.	1.1	20
151	Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. <i>American Heart Journal</i> , 2010, 160, 355-361.	1.2	20
152	New Roads, New Ruts. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 165-167.	1.1	20
153	Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 84-89.	0.3	20
154	Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. <i>EuroIntervention</i> , 2015, 10, 1425-1431.	1.4	20
155	Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen—Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oral anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. <i>American Heart Journal</i> , 2014, 167, 459-465.e1.	1.2	19
156	Optical Coherence Tomography Assessment in Patients Treated With Rotational Atherectomy Versus Modified Balloons. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009819.	1.4	19
157	Polymer coatings on drug-eluting stents: Samson's hair and Achilles' heel?. <i>EuroIntervention</i> , 2013, 9, 302-305.	1.4	19
158	Impact of sympathetic renal denervation: a randomized study in patients after renal transplantation (ISAR-denerve). <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1928-1936.	0.4	18
159	Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. <i>Clinical Research in Cardiology</i> , 2016, 105, 575-584.	1.5	18
160	Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 494-501.	0.7	17
161	Preclinical evaluation of a novel drug-eluting balloon in an animal model of in-stent stenosis. <i>Journal of Biomaterials Applications</i> , 2013, 27, 717-726.	1.2	17
162	Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). <i>American Journal of Cardiology</i> , 2016, 117, 532-538.	0.7	17

#	ARTICLE	IF	CITATIONS
163	Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries: a meta-analysis. <i>EuroIntervention</i> , 2017, 13, 483-489.	1.4	17
164	Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. <i>EuroIntervention</i> , 2020, 15, 1190-1198.	1.4	17
165	Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes. <i>Clinica Chimica Acta</i> , 2011, 412, 1350-1356.	0.5	16
166	Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis. <i>International Journal of Cardiology</i> , 2018, 252, 57-62.	0.8	16
167	Outcomes of patients treated with ultrathin-strut biodegradable polymer sirolimus-eluting stents versus fluoropolymer-based everolimus-eluting stents: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2018, 14, 224-231.	1.4	16
168	Distribution of angiographic measures of restenosis after drug-eluting stent implantation. <i>Heart</i> , 2009, 95, 1572-1578.	1.2	15
169	Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation? Editorials published in <i>JACC: Cardiovascular Interventions</i> reflect the views of the authors and do not necessarily represent the views of <i>JACC: Cardiovascular Interventions</i> or the American College of Cardiology. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1129-1132.	1.1	15
170	Rationale and design of the Prospective Longitudinal Trial of FFRCT: Outcome and Resource IMpacts study. <i>American Heart Journal</i> , 2015, 170, 438-446.e44.	1.2	15
171	Association of progression or regression of coronary artery atherosclerosis with long-term prognosis. <i>American Heart Journal</i> , 2016, 177, 9-16.	1.2	15
172	Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. <i>Cardiovascular Research</i> , 2019, 115, 1512-1518.	1.8	15
173	Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 682-692.	0.8	15
174	Pathological aspects of bioresorbable stent implantation. <i>EuroIntervention</i> , 2015, 11, V159-V165.	1.4	15
175	Temporal Trends in Strut-Level Optical Coherence Tomography Evaluation of Coronary Stent Coverage. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 1083-1093.	0.7	14
176	Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. <i>Scientific Reports</i> , 2016, 6, 33054.	1.6	14
177	Incidencia y predictores de la reestenosis recurrente tras angioplastia con balón farmacológico en reestenosis de stents farmacológicos: proyecto cooperativo ICARUS. <i>Revista Española De Cardiología</i> , 2018, 71, 620-627.	0.6	14
178	Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data. <i>EuroIntervention</i> , 2020, 15, 1451-1457.	1.4	14
179	Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 161-166.	0.7	13
180	Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2013, 165, 537-543.	1.2	13

#	ARTICLE	IF	CITATIONS
181	Second- versus first-generation sirolimus-eluting stents in diabetic patients with coronary artery disease: A randomized comparison in setting of ISAR-TEST 4 trial. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E769-76.	0.7	13
182	Prognostic value of thyroid-stimulating hormone within reference range in patients with coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1308-1315.	1.5	13
183	Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. <i>Cardiovascular Diabetology</i> , 2016, 15, 124.	2.7	13
184	Qualitative and quantitative neointimal characterization by optical coherence tomography in patients presenting with in-stent restenosis. <i>Clinical Research in Cardiology</i> , 2019, 108, 1059-1068.	1.5	13
185	Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2266-2274.	1.1	13
186	Aspirin for secondary prevention of cardiovascular disease. <i>Lancet, The</i> , 2020, 395, 1462-1463.	6.3	13
187	Angiographic and clinical outcomes of patients treated with drug-coated balloon angioplasty for in-stent restenosis after coronary bifurcation stenting with a two-stent technique. <i>EuroIntervention</i> , 2017, 12, 2132-2139.	1.4	13
188	Percutaneous coronary and structural interventions in women: a position statement from the EAPCI Women Committee. <i>EuroIntervention</i> , 2018, 14, e1227-e1235.	1.4	13
189	No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 429-432.	0.6	12
190	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: Results from the ISAR-DESIRE 2 trial. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 69-75.	0.3	12
191	Drug-eluting stent trials: too much non-inferiority, too little progress?. <i>Lancet, The</i> , 2014, 383, 386-388.	6.3	12
192	Association of increased CD8 + and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting. <i>Aids</i> , 2016, 30, 1413-1421.	1.0	12
193	Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study. <i>International Journal of Cardiology</i> , 2018, 258, 42-49.	0.8	12
194	Comparison of Vascular Closure Devices Versus Manual Compression After Femoral Artery Puncture in Women. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006074.	1.4	12
195	Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis. <i>Inflammation Research</i> , 2021, 70, 1075-1087.	1.6	12
196	Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey. <i>EuroIntervention</i> , 2016, 12, 1154-1163.	1.4	12
197	Role of Platelet Function Testing in Clinical Practice: Current Concepts and Future Perspectives. <i>Current Drug Targets</i> , 2011, 12, 1836-1847.	1.0	11
198	Stents liberadores de rapamicina sin pol�mero frente a stents liberadores de paclitaxel con pol�mero: un an�lisis de datos de pacientes procedentes de ensayos aleatorizados. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 435-442.	0.6	11

#	ARTICLE	IF	CITATIONS
199	Improving vessel healing with fully bioresorbable drug-eluting stents: more than a pipe dream?. European Heart Journal, 2016, 37, 241-244.	1.0	11
200	An FFR _{CT} diagnostic strategy versus usual care in patients with suspected coronary artery disease planned for invasive coronary angiography at German sites: one-year results of a subgroup analysis of the PLATFORM (Prospective Longitudinal Trial of FFR _{CT} : Outcome) Tj ETQq0 0 0 fgBT /Overlock 10 T	0.9	11
201	Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial. American Heart Journal, 2017, 187, 104-111.	1.2	11
202	Impact of Lesion Preparation Technique on Side Branch Compromise in Calcified Coronary Bifurcations: A Subgroup Analysis of the PREPARE-CALC Trial. Journal of Interventional Cardiology, 2020, 2020, 1-8.	0.5	11
203	Mechanism of Drug-Eluting Absorbable Metal Scaffold Restenosis. Circulation: Cardiovascular Interventions, 2020, 13, e008657.	1.4	11
204	Permanent and biodegradable polymer coatings in the absence of antiproliferative drugs in a porcine model of coronary artery stenting. EuroIntervention, 2016, 11, 1020-1026.	1.4	11
205	Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy. Clinical Research in Cardiology, 2010, 99, 13-19.	1.5	10
206	Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials. International Journal of Cardiology, 2014, 175, 484-491.	0.8	10
207	Bioresorbable Vascular Scaffolds " Will Promise Become Reality?. New England Journal of Medicine, 2015, 373, 1969-1971.	13.9	10
208	The importance of preclinical research in contemporary interventional cardiology. EuroIntervention, 2010, 6, 19-23.	1.4	10
209	Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. Indian Heart Journal, 2014, 66, 345-349.	0.2	9
210	Impact of in-hospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. American Heart Journal, 2014, 168, 862-868.e1.	1.2	9
211	Vascular response to percutaneous coronary intervention with biodegradable-polymer vs. new-generation durable-polymer drug-eluting stents: a meta-analysis of optical coherence tomography imaging trials. European Heart Journal Cardiovascular Imaging, 2018, 19, 1294-1301.	0.5	9
212	Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). Cardiovascular Revascularization Medicine, 2022, 34, 17-24.	0.3	9
213	Tools and Techniques - Clinical: Fluoroscopic balloon sizing of the aortic annulus before transcatheter aortic valve replacement (TAVR) " follow the "cusp rule" EuroIntervention, 2015, 11, 840-842.	1.4	9
214	Is there a preferable DES in diabetic patients? A critical appraisal of the evidence. Catheterization and Cardiovascular Interventions, 2008, 72, 944-949.	0.7	8
215	Serum potassium levels on admission and infarct size in patients with acute myocardial infarction. Clinica Chimica Acta, 2009, 409, 46-51.	0.5	8
216	Unmet Aspirations " Where To Now for Catheter Thrombectomy?. New England Journal of Medicine, 2013, 369, 1649-1650.	13.9	8

#	ARTICLE	IF	CITATIONS
217	Drug coated balloon angioplasty in the treatment of peripheral artery disease. Expert Review of Medical Devices, 2016, 13, 569-582.	1.4	8
218	Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 2548-2556.	1.1	8
219	Long-term effectiveness and safety of transcatheter closure of patent foramen ovale compared with antithrombotic therapy alone: a meta-analysis of six randomised clinical trials and 3,560 patients with reconstructed time-to-event data. EuroIntervention, 2018, 14, 857-867.	1.4	8
220	Evaluating the importance of sham-controlled trials in the investigation of medical devices in interventional cardiology. EuroIntervention, 2018, 14, 708-715.	1.4	8
221	Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site " CLOSURE device versus manual compression (ISAR-CLOSURE) trial. EuroIntervention, 2014, 10, 198-203.	1.4	8
222	Lesions in small coronary vessels disease: should drug-coated balloons replace drug-eluting stents as the treatment of choice?. EuroIntervention, 2011, 7, K47-K52.	1.4	8
223	Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock. Thrombosis and Haemostasis, 2011, 106, 555-558.	1.8	7
224	Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. Clinical Research in Cardiology, 2011, 100, 691-699.	1.5	7
225	Drug-Coated Balloon Angioplasty for De Novo Stenosis. JACC: Cardiovascular Interventions, 2015, 8, 2010-2012.	1.1	7
226	Prognostic Value of Cardiac Troponin T and Sex in Patients Undergoing Elective Percutaneous Coronary Intervention. Journal of the American Heart Association, 2016, 5, .	1.6	7
227	Five-year follow-up of polymer-free sirolimus and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2017, 89, 367-374.	0.7	7
228	Predicting factors for long-term survival in patients with out-of-hospital cardiac arrest " A propensity score-matched analysis. PLoS ONE, 2020, 15, e0218634.	1.1	7
229	Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus. Clinical Research in Cardiology, 2021, 110, 1586-1598.	1.5	7
230	PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent. Interventional Cardiology Review, 2017, 12, 13.	0.7	7
231	Sex and long-term outcomes after implantation of the Absorb bioresorbable vascular scaffold for treatment of coronary artery disease. EuroIntervention, 2019, 15, 615-622.	1.4	7
232	Medical device regulation in Europe " what is changing and how can I become more involved?. EuroIntervention, 2019, 15, 647-649.	1.4	7
233	Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?. Journal of Thoracic Disease, 2016, 8, E417-E423.	0.6	6
234	Increased bleeding risk during percutaneous coronary interventions by arterial hypertension. Catheterization and Cardiovascular Interventions, 2016, 88, 184-190.	0.7	6

#	ARTICLE	IF	CITATIONS
235	Incidence and predictors of reCurrent restenosis after drug-coated balloon Angioplasty for Restenosis of a drUg-eluting Stent: The ICARUS Cooperation. Revista Espanola De Cardiologia (English) Tj ETQq1 1 0.784314argBT /Over	1.0	6
236	Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery diseaseâ€”A meta-analysis of randomized clinical trials. American Heart Journal, 2020, 219, 109-116.	1.2	6
237	Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis. EuroIntervention, 2017, 13, 962-969.	1.4	6
238	Impact of stent size on angiographic and clinical outcomes after implantation of everolimus-eluting bioresorbable scaffolds in daily practice: insights from the ISAR-ABSORB registry. EuroIntervention, 2016, 12, e137-e143.	1.4	6
239	PREvention of late Stent Thrombosis by an Interdisciplinary Global European effort: PRESTIGE. European Heart Journal, 2014, 35, 2128-9.	1.0	6
240	Disappearing scaffolds, dissolving expectations. Lancet, The, 2016, 388, 2451-2452.	6.3	5
241	Postprocedural high-sensitivity troponin T and prognosis in patients with non-ST-segment elevation myocardial infarction treated with early percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2018, 19, 480-486.	0.3	5
242	Endovascular stenting in femoropopliteal arteries. Lancet, The, 2018, 392, 1491-1493.	6.3	5
243	Polymer-Free Drug-Eluting Stents. Circulation, 2020, 141, 2064-2066.	1.6	5
244	Tenâ€”Year Clinical Outcomes of Biodegradable Versus Durable Polymer Newâ€”Generation Drugâ€”Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e020165.	1.6	5
245	Outcomes of patients treated with durable polymer platinum-chromium everolimus-eluting stents: a meta-analysis of randomised trials. EuroIntervention, 2017, 13, 986-993.	1.4	5
246	State of the art: 40 years of percutaneous cardiac intervention. EuroIntervention, 2017, 13, 621-624.	1.4	5
247	Omission of aspirin after ACS or stenting in patients with oral anticoagulation â€” why have the goalposts moved?. EuroIntervention, 2019, 14, e1793-e1795.	1.4	5
248	Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention. Journal of the American Heart Association, 2022, 11, e023493.	1.6	5
249	Pharmacological prevention and management of restenosis. Expert Opinion on Pharmacotherapy, 2010, 11, 1855-1872.	0.9	4
250	The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Expert Review of Cardiovascular Therapy, 2011, 9, 999-1014.	0.6	4
251	Prognostic value of coronary computed tomographic angiography in patients with arterial hypertension. International Journal of Cardiovascular Imaging, 2012, 28, 641-650.	0.7	4
252	Bifurcation intervention with a two-stent strategy: can one size fit all?. European Heart Journal, 2016, 37, 3406-3408.	1.0	4

#	ARTICLE	IF	CITATIONS
253	Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR-LEFTMAIN and ISAR-LEFTMAIN 2 randomized clinical trials. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 1-10.	0.7	4
254	Markers of Reperfusion and Long-Term (8-Year) Prognosis after Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2018, 122, 39-46.	0.7	4
255	Strengths and Limitations of Real World Data in Patients Treated With Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007239.	1.4	4
256	Very Late Scaffold Thrombosis after Everolimus-Eluting Bioresorbable Scaffold Implantation in Patients with Unremarkable Interim Surveillance Angiography. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 361-366.	0.3	4
257	Efficacy of drug-coated balloon angioplasty in early versus late occurring drug-eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1008-1015.	0.7	4
258	Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. <i>International Journal of Cardiology</i> , 2020, 312, 42-47.	0.8	4
259	Impact of Calcified Lesion Complexity on the Success of Percutaneous Coronary Intervention With Upfront High-Speed Rotational Atherectomy or Modified Balloons - A Subgroup-Analysis From the Randomized PREPARE-CALC Trial. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 26-31.	0.3	4
260	Dynamic left ventricular outflow tract gradient resulting from Takotsubo cardiomyopathy ameliorated by intra-aortic balloon pump counterpulsation: a case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab082.	0.3	4
261	Appraising the safety and efficacy profile of left atrial appendage closure in 2016 and the future clinical perspectives. Results of the EAPCI LAAC survey. <i>EuroIntervention</i> , 2016, 12, 112-118.	1.4	4
262	Drug-Eluting or Bare-Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. <i>Journal of the American Heart Association</i> , 2021, 10, e018828.	1.6	4
263	Retrograde salvage approach to treat tibial artery perforation during attempted revascularization of a chronically occluded artery. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 741-745.	0.7	3
264	Prognosis after revascularization for left main coronary artery disease: insights from the crystal ball. <i>European Heart Journal</i> , 2015, 36, 1212-1215.	1.0	3
265	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1089-1090.	1.2	3
266	Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	3
267	Bioresorbable Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1228-1230.	1.1	3
268	Markedly different tissue types on optical coherence tomography imaging in a patient with multiple lesion drug-eluting stent in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E181-E184.	0.7	3
269	Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials. <i>Cardiovascular Revascularization Medicine</i> , 2022, 36, 99-106.	0.3	3
270	Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. <i>EuroIntervention</i> , 2014, 10, 83-89.	1.4	3

#	ARTICLE	IF	CITATIONS
271	Fallout from the ORBITA trial “ is angioplasty in a spin?. EuroIntervention, 2017, 13, 1253-1254.	1.4	3
272	What interventionalists can learn from the aviation industry. EuroIntervention, 2018, 13, 1977-1979.	1.4	3
273	Evidence-based medicine, transparency and reproducibility in research, and challenges for peer review. EuroIntervention, 2018, 13, 1615-1617.	1.4	3
274	Occupational radiation exposure in interventional cardiology “ time for further action. EuroIntervention, 2020, 16, 613-616.	1.4	3
275	Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Åbsorb MI trial. EuroIntervention, 2022, 17, 1348-1351.	1.4	3
276	Biodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial. Interventional Cardiology, 2010, 2, 267-273.	0.0	2
277	Polymer-free Sirolimus-eluting Versus Polymer-based Paclitaxel-eluting Stents: An Individual Patient Data Analysis of Randomized Trials. Revista Espanola De Cardiologia (English Ed), 2013, 66, 435-442.	0.4	2
278	Armazones vasculares bioabsorbibles en lesiones de bifurcaci3n coronaria: solo en manos expertas. Revista Espanola De Cardiologia, 2016, 69, 543-546.	0.6	2
279	Challenges in Patients with Diabetes: Improving Clinical Outcomes After Percutaneous Coronary Intervention Through EVOLving Stent Technology. Interventional Cardiology Review, 2017, 13, 40.	0.7	2
280	Influence of operator experience and PCI volume on transfemoral access techniques: A collaboration of international cardiovascular societies. Cardiovascular Revascularization Medicine, 2018, 19, 143-150.	0.3	2
281	40 years of angioplasty “ remembering patients and pioneers. EuroIntervention, 2017, 12, 2041-2043.	1.4	2
282	The discovery of X-rays, the fate of atomic bomb survivors, and the impact on modern interventional cardiology. EuroIntervention, 2018, 14, 129-131.	1.4	2
283	How should I treat a restenosis after superficial femoral artery stenting?. EuroIntervention, 2013, 8, 1342-1345.	1.4	2
284	Patient focus in interventional cardiology: proceedings of the 2018 summit of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) “ Nice, France, 20-21 June 2018. EuroIntervention, 2019, 14, 1720-1723.	1.4	2
285	A prospective trial of a novel <sc>low-dose paclitaxel-coated</sc> balloon therapy in patients with restenosis in <sc>drug-eluting</sc> coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent <sc>In-stent</sc> REstenosis <sc>3A</sc> (ISAR-DESIRE 3A). Catheterization and Cardiovascular Interventions, 2022, 99, 754-762.	0.7	2
286	Migration of inferior vena cava stent into right ventricle: two- and three-dimensional echocardiographic imaging. European Heart Journal Cardiovascular Imaging, 2009, 10, 370-371.	0.5	1
287	Bioresorbable Vascular Scaffolds in Coronary Bifurcation Lesions: Only in Expert Hands. Revista Espanola De Cardiologia (English Ed), 2016, 69, 543-546.	0.4	1
288	TCT-26 Predictors of Bailout Rotational Atherectomy in Patients With Complex Calcified Coronary Artery Disease: A Pooled Analysis From the Randomized ROTAXUS and PREPARE-CALC Trials. Journal of the American College of Cardiology, 2019, 74, B26.	1.2	1

#	ARTICLE	IF	CITATIONS
289	Angiographic performance of everolimus-eluting stents for the treatment of coronary in-stent restenosis in daily practice. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 857-862.	0.7	1
290	Biodegradable- Versus Durable-Polymer DES in ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 649-652.	1.1	1
291	Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2815-2826.	0.7	1
292	Acute myocardial infarction in a young endurance athlete caused by probable plaque erosion. <i>EuroIntervention</i> , 2017, 13, e246-e247.	1.4	1
293	Regulation of coronary stents – physicians as stakeholders. <i>EuroIntervention</i> , 2017, 12, 1679-1680.	1.4	1
294	Time does not heal all wounds: very late stent thrombosis eight years after implantation of a sirolimus-eluting stent due to positive remodelling, saccular evaginations and marked vascular inflammation. <i>EuroIntervention</i> , 2013, 9, 412-413.	1.4	1
295	Will this trial change my practice? ABSORB II trial (a bioresorbable vascular scaffold versus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tt5	1.4	1
296	Peer review at <i>EuroIntervention</i> – a rough guide and an expression of thanks. <i>EuroIntervention</i> , 2016, 12, 1197-1199.	1.4	1
297	Continuing medical education and sponsorship by the healthcare industry – new opportunities and challenges. <i>EuroIntervention</i> , 2017, 13, e137-e138.	1.4	1
298	OUP accepted manuscript. <i>European Heart Journal</i> , 2022, , .	1.0	1
299	Response to Letter Regarding Article, “Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention” <i>Circulation</i> , 2012, 126, .	1.6	0
300	The battle against stent thrombosis – to protect and to serve. <i>Lancet</i> , The, 2012, 380, 1365-1367.	6.3	0
301	A case where the principle of “one question, one answer” may work better. <i>American Heart Journal</i> , 2012, 163, 133-135.	1.2	0
302	TCT-353 Long-Term Outcomes of Biodegradable Polymer Drug-Eluting Stents versus Durable Polymer Sirolimus-Eluting Stents in Patients with Diabetes: A Pooled Analysis of Individual Patient Data from the ISAR-TEST 4 and LEADERS Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2012, 60, B100.	1.2	0
303	AS-095 Differential Vascular Healing Patterns with Rapid Absorption Biodegradable Polymer Sirolimus-Eluting Stents versus Durable Polymer Everolimus-Eluting Stents. <i>American Journal of Cardiology</i> , 2012, 109, S47-S48.	0.7	0
304	Treatment of coronary drug-eluting stent restenosis: a journey back to the future?. <i>Expert Review of Medical Devices</i> , 2013, 10, 423-427.	1.4	0
305	TCT- 460 Bivalirudin versus heparin during percutaneous coronary intervention: a meta-analysis of randomized trials. <i>Journal of the American College of Cardiology</i> , 2014, 64, B135.	1.2	0
306	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2266-2267.	1.2	0

#	ARTICLE	IF	CITATIONS
307	Biodegradable polymer drug-eluting stents: ready for US prime time?. Cardiovascular Revascularization Medicine, 2015, 16, 323-325.	0.3	0
308	TCT-414 Two-year outcomes of patients with acute coronary syndrome versus stable coronary disease undergoing bioresorbable scaffold implantation. Journal of the American College of Cardiology, 2016, 68, B168.	1.2	0
309	Biodegradable polymer drug-eluting stents: caveat emptor. Lancet, The, 2017, 390, 1814-1816.	6.3	0
310	TCT-283 10-Year Clinical Outcomes From a Trial of 3 Limus-Eluting Stents With Different Polymer Coatings in Diabetic Patients With Coronary Artery Disease: Results From the ISAR-TEST 4 Randomized Trial. Journal of the American College of Cardiology, 2019, 74, B282.	1.2	0
311	TCT-661 Angiographic Results of Everolimus-Eluting Stents for the Treatment of In-Stent Restenosis. Journal of the American College of Cardiology, 2019, 74, B649.	1.2	0
312	TCT-11 Everolimus-Eluting Bioresorbable Scaffolds Versus Drug-Eluting Stents in Patients With Acute Myocardial Infarction: 2-Year Results of the Randomized ISAR-Absorb MI Trial. Journal of the American College of Cardiology, 2019, 74, B11.	1.2	0
313	Shedding Light on the Optimal Management of Patients Presenting With Transient ST-Segment Elevation. JACC: Cardiovascular Interventions, 2019, 12, 2283-2285.	1.1	0
314	Optical Coherence Tomography Tissue Coverage and Characterization with Grey-Scale Signal Intensity Analysis After Bifurcation Stenting with a New Generation Bioabsorbable Polymer Drug-Eluting Stent. Cardiovascular Revascularization Medicine, 2020, 21, 277-285.	0.3	0
315	Do outcomes following intervention for drug-eluting stent restenosis depend on whether the restenosed stent was polymer-free or polymer-coated?. Revista Espanola De Cardiologia (English Ed), 2020, 73, 225-231.	0.4	0
316	Reply. Journal of the American College of Cardiology, 2020, 76, 1392-1393.	1.2	0
317	Outcomes after complete dissolution of everolimus-eluting bioresorbable scaffolds implanted during routine practice. Revista Espanola De Cardiologia (English Ed), 2020, 74, 584-590.	0.4	0
318	Durable or Biodegradable Polymer Stent Coatings. Circulation, 2021, 143, 1092-1094.	1.6	0
319	Choice of Primary Endpoint for Trials Comparing Balloon Angioplasty and Stenting. JACC: Cardiovascular Interventions, 2021, 14, 709.	1.1	0
320	Primary Percutaneous Coronary Intervention. , 2010, , 65-77.		0
321	Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention. EuroIntervention, 2016, 11, e1275-e1282.	1.4	0
322	EuroPCR 2017, late-breaking clinical trials and EuroIntervention. EuroIntervention, 2017, 13, e499-e502.	1.4	0
323	In-Stent Restenosis. , 2018, , 469-481.		0
324	The use and impact of clinical practice guidelines in interventional cardiology. EuroIntervention, 2018, 14, 607-608.	1.4	0

#	ARTICLE	IF	CITATIONS
325	The ESC Congress 2018 and the legacy of Eugene Braunwald. EuroIntervention, 2018, 14, 1067-1068.	1.4	0
326	The year in review: coronary interventions. EuroIntervention, 2020, 15, 1534-1547.	1.4	0
327	Angiography-derived quantitative flow ratio guidance of coronary intervention: measure twice, cut once. Lancet, The, 2021, , .	6.3	0